Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 110 participants.

Also called NCT03226210

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 110 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT03226210
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03226210. Randomized; single masking; primary purpose treatment. Start 2015-02-01 (actual); primary completion 2016-05-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Comparison of Efficacy and Safety of Prandilin and NovoRapid in Newly Diagnosed Type 2 Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
aspart insulin or lipro insulin
Lead sponsor
Nanjing First Hospital, Nanjing Medical University (class: other)

Record details

Record id
cardio:ct-nct03226210
Content hash
eea665f5e5e5d58e78c9c674e19abcd4dbee70ca42d3c2471ea91499484ef4b2